Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Notable Labs Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for patients with cancer. Through its proprietary Predictive Medicines Platform, the firm predicts whether or not that patient is likely to respond to that specific therapeutic. The company's Predictive Medicines Platform is designed to identify and select patients expected to be clinically responsive prior to their treatment to improve patient outcomes and fast-track clinical development. The firm's product candidate, Volasertib, is a Polo-like Kinase 1 inhibitor. Notable Labs was founded on January 31, 2000 and is headquartered in Foster City, CA.

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates

Conference Call and Webcast at 8:30am Eastern Time Today Conference Call and Webcast at 8:30am Eastern Time Today

VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update

Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings

VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq Rules

TEL AVIV, Israel, May  12, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also issued to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 6,349,208 of VBL’s ordinary shares. The warrants have an exercise price of $1.45 per ordinary share, are immediately exercisable and will expire on November 11, 2020. The registered direct offering closed on May 11, 2020.

VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vascular Biogenics (VBLT) Q1 Earnings Expected to Decline

TEL AVIV, Israel, May  07, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 6,349,208 of VBL’s ordinary shares. The warrants have an exercise price of $1.45 per ordinary share, will be immediately exercisable and will expire 18 months from the date of issuance.

VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

TEL AVIV, Israel, May  06, 2020  (GLOBE NEWSWIRE) --  VBL Therapeutics  (Nasdaq:  VBLT ), (the “Company”) today announced new data implicating the potential of its anti-MOSPD2 antibodies for treatment of nonalcoholic steatohepatitis (NASH) and colitis. Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.  VBL's ePoster entitled “MOSPD2: A novel therapeutic target for the treatment of inflammatory digestive disorders,” was presented at the Digestive Disease Week® (DDW) 2020 virtual meeting. VBL's study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction.

VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW

Data were published in a peer-review manuscript in Clinical & Experimental Immunology Data were published in a peer-review manuscript in Clinical & Experimental Immunology

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

TEL AVIV, Israel, April  21, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA has approved a budget of approximately $1.8 million for the VB-111 project during 2020, with 50% of this amount as an IIA grant. The funds will support the continued development of VBL's lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. VB-111 is currently being evaluated in a Phase 3 potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer.

VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111

TEL AVIV, Israel, April  06, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that it has reached a milestone event under its collaborative agreement with a world-leading European animal health company, evaluating use of VB-201 for veterinary applications. Upon reaching this milestone, VBL is entitled to receive an undisclosed cash payment.

VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use

TEL AVIV, Israel, April  02, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that following the positive interim analysis in the OVAL study,   its Japanese licensee NanoCarrier Co., Ltd. (TSE Mothers: 4571), intends to extend the ongoing  global  Phase 3 OVAL clinical trial in ovarian cancer to patients in Japan. NanoCarrier will be responsible for all required operations and expenses related to the study in Japan.   VBL and NanoCarrier Co. Ltd. signed an exclusive license agreement in 2017 for the development, commercialization, and supply of VB-111 in Japan. There are more than 10,000 women diagnosed with ovarian cancer in Japan with more than 5,000 associated deaths annually. Therefore, opening clinical sites in Japan will enable to expedite the OVAL trial globally as well as the potential registration of the VB-111 in Japan upon positive outcome.

Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier

Vascular Biogenics: A Buy On Promising Cancer Therapy

TEL AVIV, Israel, March  26, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced an encouraging outcome of the planned interim analysis in the OVAL study, a double-blind controlled potential-registration study in patients with platinum-resistant ovarian cancer. The OVAL independent Data Safety Monitoring Committee (DSMC), reviewed un-blinded data and assessed CA-125 response, measured according to the GCIG criteria, in the first 60 enrolled subjects evaluable for CA-125 analysis. The DSMC confirmed that the study met the interim pre-specified efficacy criterion, of an absolute percentage advantage of 10% or higher CA-125 response rate for the VB-111 treatment arm, and recommended the study  continuance .

VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2019 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor in VBL.

Will VBL Continue to Surge Higher?

Vascular Biogenics Ltd. VBLT) CEO Dror Harats on Q3 2019 Results - Earnings Call Transcript

TEL AVIV, Israel, Nov.  06, 2019  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that an investigational new drug (IND) application has received clearance from the U.S. Food and Drug Administration (FDA). The IND is for a Phase 2 randomized, controlled, clinical trial of VB-111 in rGBM patients undergoing a second surgery. In this new study, VB-111 will be administrated either before and after the surgery (neo-adjuvant and adjuvant therapy) or just after the surgery (adjuvant therapy) and will be compared to a standard of care control cohort. The IND was submitted by Patrick Wen, M.D., Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on behalf of a group of top neuro-oncology US medical centers.

VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

Vascular Biogenics' (VBLT) CEO Dror Harats on Q2 2019 Results - Earnings Call Transcript

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2019 Results - Earnings Call Transcript

Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2018 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 41.18% and -53.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

News for Vascular Biogenics Stock (VBLT)